Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition
- 1 December 2021
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 100 (6), 1214-1226
- https://doi.org/10.1016/j.kint.2021.08.022
Abstract
No abstract availableThis publication has 75 references indexed in Scilit:
- Onco-NephrologyClinical Journal of the American Society of Nephrology, 2012
- Onco-NephrologyClinical Journal of the American Society of Nephrology, 2012
- Acute kidney injuryThe Lancet, 2012
- Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpointsProceedings of the National Academy of Sciences of the United States of America, 2011
- Cellular pathophysiology of ischemic acute kidney injuryJCI Insight, 2011
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancerNature Chemical Biology, 2010
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- The endothelial cell in ischemic acute kidney injury: implications for acute and chronic functionKidney International, 2007
- Mutations of the BRAF gene in human cancerNature, 2002